Instructions Memoplant film-coated tablets 40 mg No. 20
Composition
active ingredient: dry extract (EGb 761®) from Ginkgo biloba leaves (35-67:1), standardized to 8.8-10.8 mg of ginkgo flavone glycosides and to 2.0-2.8 mg of terpene lactones, of which 1.12-1.36 mg are ginkgolides A, B and C and 1.04-1.28 mg are bilobalide, and no more than 0.2 μg of ginkgolic acids, extractant: acetone 60% (m/m);
1 film-coated tablet contains 40 mg of dry extract (EGb 761®) from Ginkgo biloba leaves (35-67:1), standardized to 8.8-10.8 mg of ginkgo flavone glycosides and to 2.0-2.8 mg of terpene lactones, of which 1.12-1.36 mg are ginkgolides A, B and C and 1.04-1.28 mg are bilobalide, and no more than 0.2 μg of ginkgolic acids, extractant: acetone 60% (m/m);
excipients: croscarmellose sodium, antifoam agent SE 2, colloidal anhydrous silica, hypromellose, lactose monohydrate, macrogol 1500, magnesium stearate, corn starch, microcrystalline cellulose, talc, titanium dioxide (E 171), yellow iron oxide (E 172) and yellow iron hydroxide (E 172).
Dosage form
Film-coated tablets.
Main physicochemical properties: yellow, smooth, round, film-coated tablets.
Pharmacotherapeutic group
Drugs used in dementia. ATX code N06D X02.
Pharmacological properties
Pharmacodynamics.
A herbal preparation that normalizes cellular metabolism, blood rheological properties, and microcirculation. Improves cerebral blood flow and oxygen and glucose supply to the brain, prevents erythrocyte aggregation, inhibits platelet activation factor. Has a dose-dependent regulatory effect on the vascular system, stimulates the production of endothelium-dependent relaxing factor (nitric oxide – NO), dilates small arteries, increases venous tone, thereby regulating blood filling of vessels. Reduces vascular wall permeability (anti-edema effect both at the brain and peripheral levels). Has an antithrombotic effect (due to stabilization of platelet and erythrocyte membranes, influence on prostaglandin synthesis, reduction of the action of biologically active substances and platelet-activating factor). Prevents the formation of free radicals and lipid peroxidation of cell membranes. Normalizes the release, reabsorption and catabolism of neurotransmitters (norepinephrine, dopamine, acetylcholine) and their ability to bind to receptors. Has an antihypoxic effect, improves metabolism in organs and tissues, promotes the accumulation of macroergs in cells, increases the utilization of oxygen and glucose, normalizes mediator processes in the central nervous system.
Pharmacokinetics.
Active ingredient – standardized dry extract of Ginkgo biloba (EGb 761®): 24% heterosides and 6% ginkgolides-bilobalides (ginkgolide A, B and bilobalide C).
In studies involving volunteers, only the pharmacokinetic parameters of the terpene fractions were studied. When administered orally, the bioavailability of ginkgolides A, B and bilobalide C is 80-90%. The maximum concentration is reached 1-2 hours after taking the drug. The half-lives are approximately 4 hours (bilobalide, ginkgolide A) and 10 hours (ginkgolide B).
These substances do not break down in the body, are almost completely excreted in the urine, and a small amount is excreted in the feces.
Indication
Cognitive deficits of various genesis (dyscirculatory encephalopathy, due to stroke, traumatic brain injury, in old age, manifested by attention and/or memory disorders, decreased intellectual abilities, feelings of fear, sleep disturbances) and neurosensory deficits of various genesis (senile macular degeneration, diabetic retinopathy);
intermittent claudication in chronic obliterating arteriopathy of the lower extremities (Fontaine stage II);
Hearing impairment, tinnitus, dizziness and impaired coordination, mainly of vascular origin.
Contraindication
Hypersensitivity to the components of the drug.
Interaction with other medicinal products and other types of interactions
Interactions with anticoagulants cannot be excluded. In a placebo-controlled, double-blind study of 7 days duration in 50 volunteers, no interaction was found between EGb 761® (daily dose 240 mg) and acetylsalicylic acid (daily dose 500 mg).
Application features
The first signs of improvement appear 1 month after the start of treatment.
Since this medicinal product contains lactose, it is contraindicated in patients with congenital galactosemia, glucose or galactose malabsorption syndrome or lactase deficiency.
It is possible that taking medications containing ginkgo extract may trigger seizures in patients with epilepsy. A causal relationship between the phenomenon and taking the medication has not been established.
Use during pregnancy and breastfeeding
Due to the lack of clinical data, the drug is not recommended for use during pregnancy or breastfeeding.
The ability to influence the speed of reactions when driving vehicles or other mechanisms
During treatment, caution should be exercised when driving or operating machinery.
Method of administration and doses
Prescribe 1 tablet 3 times a day during meals. Wash down with ½ glass of water. The average duration of the course of treatment is 3 months.
Children.
There is insufficient experience with the use of the drug in children.
Overdose
There is no information on overdose of the drug.
Side effects
Possible side effects:
– from the digestive tract, including dyspeptic phenomena, nausea, vomiting;
– from the nervous system: headache, dizziness;
Immune system disorders: hypersensitivity reactions, including angioedema, urticaria, dyspnea.
Skin: skin inflammation, redness, swelling, itching, rash, eczema.
After long-term treatment with Memoplant, bleeding was observed in isolated cases.
Expiration date
5 years.
Storage conditions
Store at a temperature not exceeding 25 °C in places inaccessible to children.
Packaging
Blisters of 10 tablets; 2 blisters in a cardboard box. Blisters of 20 tablets; 3 blisters in a cardboard box.
Vacation category
Without a prescription.
Producer
Dr. Wilmar Schwabe GmbH & Co. KG.
Address
Wilmar-Schwabe-Strasse 4, 76227 Karlsruhe, Germany.
